James C Momtazee Roivant Sciences Ltd. (ROIV) insider trading activity

James C Momtazee is of Roivant Sciences Ltd.. Currently has a direct ownership of 96,670 shares of ROIV, which is worth approximately $1.11 Million. The most recent transaction as insider was on Jul 17, 2025, when has been sold 241 shares (Common Shares) at a price of $11.65 per share, resulting in proceeds of $2,807. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 96.7K

1.0% 3M change

22.23% 12M change

Total Value Held $1.11 Million

JAMES C MOMTAZEE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 17 2025	SELL Payment of exercise price or tax liability	$2,807 $11.65 p/Share	241 Reduced 0.25%	96,670 Common Shares
Jul 17 2025	BUY Grant, award, or other acquisition	-	1,201 Added 1.22%	96,911 Common Shares
Apr 17 2025	SELL Payment of exercise price or tax liability	$2,801 $10.15 p/Share	276 Reduced 0.29%	95,710 Common Shares
Apr 17 2025	BUY Grant, award, or other acquisition	-	1,379 Added 1.42%	95,986 Common Shares
Jan 23 2025	SELL Payment of exercise price or tax liability	$3,430 $11.21 p/Share	306 Reduced 0.32%	94,607 Common Shares
Jan 23 2025	BUY Grant, award, or other acquisition	-	1,248 Added 1.3%	94,913 Common Shares
Oct 21 2024	BUY Grant, award, or other acquisition	-	1,231 Added 1.3%	93,665 Common Shares
Sep 12 2024	SELL Other acquisition or disposition	$37,038 $12.12 p/Share	3,056 Reduced 3.2%	92,434 Common Shares
Sep 10 2024	BUY Grant, award, or other acquisition	-	16,406 Added 14.66%	95,490 Common Shares
Jul 23 2024	BUY Grant, award, or other acquisition	-	1,555 Added 1.93%	79,091 Common Shares
Apr 24 2024	SELL Payment of exercise price or tax liability	$3,193 $10.9 p/Share	293 Reduced 0.38%	77,536 Common Shares
Apr 24 2024	BUY Grant, award, or other acquisition	-	1,490 Added 1.88%	77,829 Common Shares
Jan 19 2024	BUY Grant, award, or other acquisition	-	1,570 Added 2.02%	76,339 Common Shares
Oct 17 2023	SELL Other acquisition or disposition	$7,076 $10.3 p/Share	687 Reduced 0.91%	74,769 Common Shares
Sep 18 2023	SELL Other acquisition or disposition	$75,419 $11.17 p/Share	6,752 Reduced 8.38%	73,862 Common Shares
Sep 12 2023	BUY Grant, award, or other acquisition	-	17,825 Added 18.11%	80,614 Common Shares
Jul 03 2023	BUY Grant, award, or other acquisition	-	1,664 Added 2.58%	62,789 Common Shares
Apr 03 2023	BUY Grant, award, or other acquisition	-	1,351 Added 2.16%	61,125 Common Shares
Jan 03 2023	BUY Grant, award, or other acquisition	-	2,447 Added 3.93%	59,774 Common Shares
Oct 31 2022	BUY Grant, award, or other acquisition	-	3,404 Added 5.61%	57,327 Common Shares
Oct 16 2022	BUY Grant, award, or other acquisition	-	1,594 Added 2.07%	75,456 Common Shares
Sep 15 2022	BUY Grant, award, or other acquisition	-	50,000 Added 48.11%	53,923 Common Shares
Jul 20 2022	BUY Grant, award, or other acquisition	-	3,923 Added 50.0%	3,923 Common Shares

Also insider at

BBIO

BridgeBio Pharma, Inc. Healthcare

JCM

James C Momtazee

London, X0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ROIV shares.

Notify only if

Value

Insider Trading

Get notified when an Roivant Sciences Ltd. insider buys or sells ROIV shares.

Notify only if

Operation

Value

Type

News

Receive news related to Roivant Sciences Ltd.

Track Activities on ROIV

Account